CADRENAL THERAPEUTICS INC (CVKD) Stock News

NASDAQ:CVKD - Nasdaq - US1276362076 - Common Stock - Currency: USD

11.41 -0.31 (-2.65%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CVKD Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Benzinga - Mentions: CYCC TLPH BNR ORGO ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

11 days ago - By: Benzinga - Mentions: JAGX WINT PRPO DARE ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

2 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

a year ago - By: BusinessInsider

News Image

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

2 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

3 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

4 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

5 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

6 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

6 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

7 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

7 months ago - By: Cadrenal Therapeutics

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

7 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

9 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

9 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

9 months ago - By: Cadrenal Therapeutics, Inc.

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

10 months ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

a year ago - By: InvestorPlace

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

a year ago - By: Cadrenal Therapeutics, Inc. - Mentions: ABT

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

a year ago - By: InvestorPlace

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

a year ago - By: InvestorPlace - Mentions: RLYB JNJ RENT ALPN ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

a year ago - By: InvestorPlace - Mentions: JOAN STI BNAI VJET ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

a year ago - By: Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update